Kymera Therapeutics, Inc. (KYMR)
$118.15-$2.08 (-1.73%) Today
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 95 | 2,720,471 | $290.72M |
| Grant or award | 12 | 174,680 | |
| Option exercise | 15 | 446,544 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
68 Form 4 filings on record, the earliest from Dec 2, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Bruce N. Jacobs - Officer | Option exercise | Common Stock | 79,220 | $2.08 | $165K | |
| Bruce N. Jacobs - Officer | Open-market sale | Common Stock | 79,220 | $50.00 | $3.96M | |
| Bruce N. Jacobs - Officer | Option exercise | Stock Option (Right to Buy) | 42,246 | $0.00 | - | |
| Bruce N. Jacobs - Officer | Option exercise | Stock Option (Right to Buy) | 36,974 | $0.00 | - | |
| Nello Mainolfi - Officer | Option exercise | Common Stock | 30,000 | $2.08 | $62K | |
| Nello Mainolfi - Officer | Open-market sale | Common Stock | 30,000 | $49.00 | $1.47M | |
| Nello Mainolfi - Officer | Option exercise | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Brian Adams - Officer | Grant or award | Common Stock | 52,500 | $0.00 | - | |
| Brian Adams - Officer | Grant or award | Stock Option (Right to Buy) | 105,000 | $0.00 | - | |
| BVF PARTNERS L P - Director | Open-market purchase | Common Stock, $0.0001 par value | 142,604 | $44.00 | $6.27M | |
| BVF PARTNERS L P - Director | Open-market purchase | Common Stock, $0.0001 par value | 115,783 | $44.00 | $5.09M | |
| BVF PARTNERS L P - Director | Open-market purchase | Common Stock, $0.0001 par value | 58,780 | $44.00 | $2.59M | |
| BVF PARTNERS L P - Director | Grant or award | Stock Option (Right to Buy) | 16,000 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 55,191 | $44.00 | $2.43M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 600,309 | $44.00 | $26.41M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Prefunded Warrants | 55,191 | $44.00 | $2.43M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Prefunded Warrants | 600,309 | $44.00 | $26.41M | |
| John Maraganore | Grant or award | Stock Option (Right to Buy) | 16,000 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non-Qualified Stock Option (right to buy) | 16,000 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non-Qualified Stock Option (right to buy) | 16,000 | $0.00 | - | |
| Pamela Esposito | Option exercise | Common Stock | 2,500 | $29.55 | $74K | |
| Pamela Esposito | Open-market sale | Common Stock | 2,500 | $49.00 | $123K | |
| Pamela Esposito | Option exercise | Stock Option (Right to Buy) | 2,500 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 68 KYMR filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Kymera Therapeutics, Inc. (KYMR) had 22 insider filings in the last 90 days, with the most recent on 2026-07-27. The full record for KYMR runs to 68 Form 4 filings, the earliest from 2024-12-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of KYMR were filed in the last 90 days. 9 purchases are on record for this company.
95 insider sales of KYMR were filed in the last 90 days, totaling $290.72M.
This page tracks KYMR Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add KYMR to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
